Measuring the effect of a Tris-Indolyl Compound on PC3 Cells

Abstract

Event Abstract Back to Event Measuring the effect of a Tris-Indolyl Compound on PC3 Cells Amanda F. Wallace1, Timothy Tolentino1* and Christine Whitlock1* 1 Georgia Southern University, United States The ability of Compound B to reduce the viability of prostate cancer cells was tested via MTS cell viability assays on PC3 (Prostate Cancer cell line). Compound B, a novel tris-indolyl iron chelating compound, was tested by the National Cancer Institute’s Developmental Therapeutics Program and shown to have anticancer activity. Building upon these finding, Compound B was synthesis in our lab and further testing was done. Here, MTS assays were used to measure Compound B’s effect on the viability PC3 cells at varying concentration. Results showed that PC3 cells exposed to Compound B at a 69.8 μM concentration showed a 40% decrease in viability. Acknowledgements Cell culture facilities were provided by the GSU Department of Chemistry & Biochemistry. Flow Cytometry facilities were provided by GSU Department of Biology References Sears,R.B.,Carpenter,R.A., Whitlock,C.R, A General Synthesis of Tris-Indole Derivatives as Potential Iron Chelators, Molecules 2005, 10, 488-491 Keywords: PC3 cancer cell line, Anticancer properties, Iron chelators, MTS assay, Apoptosis assay, tris-indolyl Conference: National Organization for the Professional Advancement of Black Chemists and Chemical Engineers (NOBCChE) 45th Annual Conference , Orlando, Florida, United States, 17 Sep - 20 Sep, 2018. Presentation Type: Poster Presentation Topic: Medicinal Chemistry Citation: Wallace AF, Tolentino T and Whitlock C (2019). Measuring the effect of a Tris-Indolyl Compound on PC3 Cells. Front. Chem. Conference Abstract: National Organization for the Professional Advancement of Black Chemists and Chemical Engineers (NOBCChE) 45th Annual Conference . doi: 10.3389/conf.fchem.2018.01.00061 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 18 Oct 2018; Published Online: 17 Jan 2019. * Correspondence: Dr. Timothy Tolentino, Georgia Southern University, Statesboro, United States, ttolentino@georgiasouthern.edu Dr. Christine Whitlock, Georgia Southern University, Statesboro, United States, cwhitlock@georgiasouthern.edu Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Amanda F Wallace Timothy Tolentino Christine Whitlock Google Amanda F Wallace Timothy Tolentino Christine Whitlock Google Scholar Amanda F Wallace Timothy Tolentino Christine Whitlock PubMed Amanda F Wallace Timothy Tolentino Christine Whitlock Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.